Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Xyphos Biosciences Inc. manages a portfolio in the Biotechnology & Pharmaceuticals technology area. There are currently 2 pending office actions across the portfolio. These actions are distributed among 2 distinct examiners and 2 distinct art units, indicating a spread of technical review across the USPTO. This distribution suggests that the company's research and development efforts may span multiple specialized sub-fields within the biotechnology sector, requiring different sets of examiner expertise.
The busiest examiner for the company is BUNNER, BRIDGET E, who is currently handling 1 busiest examiner pending action. This means the 2 pending office actions are split between the busiest examiner and other personnel. The use of 2 distinct art units suggests that the company's biological or pharmaceutical innovations are being evaluated under different specialized criteria. For a practitioner, this indicates a need to manage prosecution strategies that are consistent across different examining groups while addressing the specific requirements of each art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BUNNER, BRIDGET E | 1 | 64.6% | +19.8% |
| KAUFMAN, CLAIRE M | 1 | 63.3% | +51.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18606822 | NON-NATURAL NKG2D RECEPTORS THAT DO NOT DIRECTLY SIGNAL THE CELLS TO WHICH THEY ARE ATTACHED | BUNNER, BRIDGET E | — |
| 18568387 | ANTIBODY-NKG2D LIGAND DOMAIN FUSION PROTEIN | KAUFMAN, CLAIRE M | — |
| Art Unit | Apps |
|---|---|
| 1647 | 1 |
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18606822 | NON-NATURAL NKG2D RECEPTORS THAT DO NOT DIRECTLY SIGNAL THE CELLS TO WHICH THEY ARE ATTACHED | BUNNER, BRIDGET E | 1647 | §112DP | Non-Final OA | — | Pending | Mar 15, 2024 |
| 18568387 | ANTIBODY-NKG2D LIGAND DOMAIN FUSION PROTEIN | KAUFMAN, CLAIRE M | 1674 | §112DP | Non-Final OA | — | Pending | Dec 08, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialXyphos Biosciences Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Bridget E Bunner has the most, with 1 of Xyphos Biosciences Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
